Published in Clin Diabetes on October 01, 2014
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS One (2016) 0.76
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Des Devel Ther (2017) 0.75
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes (2017) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Use and abuse of HOMA modeling. Diabetes Care (2004) 16.97
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis (2007) 8.79
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 7.81
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 6.40
'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis (2012) 5.70
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA (2010) 4.45
Retinopathy in diabetes. Diabetes Care (2004) 4.25
The role of gut hormones in glucose homeostasis. J Clin Invest (2007) 3.36
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med (2004) 3.34
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
The burden of treatment failure in type 2 diabetes. Diabetes Care (2004) 3.14
Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract (2010) 2.75
Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr (2003) 2.45
Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant (2008) 2.21
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab (2009) 2.19
Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care (2005) 2.07
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care (2009) 1.80
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract (2010) 1.78
Defining and characterizing the progression of type 2 diabetes. Diabetes Care (2009) 1.77
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med (2010) 1.70
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin (2009) 1.62
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol (2012) 1.60
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord (2010) 1.60
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract (2009) 1.47
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab (2009) 1.44
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab (2010) 1.43
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin (2012) 1.34
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin (2009) 1.22
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract (2011) 1.20
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab (2011) 1.13
Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin (2009) 1.12
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab (2011) 1.11
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res (2011) 1.06
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol (2012) 1.05
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res (2011) 1.02
Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet (2011) 0.95
Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care (2008) 0.94
Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabet Med (2013) 0.94
Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metab Dispos (2012) 0.86
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol (2011) 0.86
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab (2011) 0.77
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol (2011) 0.77
Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care (2013) 4.85
Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care (2014) 1.64
Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother (2010) 1.47
Activation of the aryl hydrocarbon receptor increases pulmonary neutrophilia and diminishes host resistance to influenza A virus. Am J Physiol Lung Cell Mol Physiol (2005) 1.14
Aryl hydrocarbon receptor activation reduces dendritic cell function during influenza virus infection. Toxicol Sci (2010) 1.11
Aryl hydrocarbon receptor activation impairs the priming but not the recall of influenza virus-specific CD8+ T cells in the lung. J Immunol (2006) 1.09
Effectiveness of a pharmacist-nurse intervention on resolving medication discrepancies for patients transitioning from hospital to home health care. Am J Health Syst Pharm (2009) 0.98
Nurse identified hospital to home medication discrepancies: implications for improving transitional care. Geriatr Nurs (2010) 0.96
Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Investig Drugs (2008) 0.91
Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin Ther (2009) 0.89
Ethnicity/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia. Am J Cardiovasc Drugs (2010) 0.89
Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin Ther (2005) 0.86
Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist. J Am Pharm Assoc (2003) (2009) 0.79
Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec. Drugs (2012) 0.79
Screening for undiagnosed cognitive impairment in homebound older adults. Consult Pharm (2009) 0.78
Inhaled dry powder insulin for the treatment of diabetes mellitus. Clin Ther (2007) 0.77
Challenges of medication management in hospitalized patients with Parkinson's disease. Am J Health Syst Pharm (2010) 0.76
Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics. Am J Nephrol (2016) 0.75
The Mini-Cog: a rapid dementia screening tool suitable for pharmacists' use. Consult Pharm (2007) 0.75
Response to comments on Evert et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes care 2013;36:3821-3842. Diabetes Care (2014) 0.75
Continuation of oral medications when insulin is initiated. South Med J (2010) 0.75
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol (2020) 0.75
Transitional care: exploring the home healthcare nurse's role in medication management. Home Healthc Nurse (2012) 0.75
2016 Prescott Lecture: Diabetes education-leadership through action. J Am Pharm Assoc (2003) (2016) 0.75
Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. Consult Pharm (2009) 0.75
Calling All Educators: Let Us Know Your Educational Needs. Diabetes Spectr (2014) 0.75